Navigation Links
Clarient to Present at Noble Financial's 5th Annual Equity Conference on Tuesday, June 9th
Date:6/3/2009

Presentation Scheduled for 11:35am EDT

ALISO VIEJO, Calif., June 3 /PRNewswire-FirstCall/ -- Clarient, Inc. (Nasdaq: CLRT), a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that Ron Andrews, CEO and Vice Chairman, is scheduled to make an investor presentation at Noble Financial's 5th Annual Equity Conference at 11:35am EDT on Tuesday, June 9, 2009. The conference will be held at the Seminole Hard Rock Hotel and Casino in Hollywood, Florida on June 8-9, 2009.

A live webcast of the presentation will be available via a link provided at http://www.clarientinc.com/investor. An archived replay of the presentation will be available for a period of 90 days from the date of the presentation.

About Clarient

Clarient combines innovative diagnostic technologies with world class pathology expertise to assess and characterize cancer. Clarient's mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies, such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary "companion" diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient is a Safeguard Scientifics, Inc. partner company. www.clarientinc.com

    Press Contact:
    Kristy DelMuto
    Gregory FCA
    (610) 228-2118
    kristy@gregoryfca.com

    Investor Contact:
    Matt Clawson
    Allen & Caron Inc
    (949) 474-4300
    matt@allencaron.com


'/>"/>
SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
2. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
3. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
4. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
5. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
6. Jim Agnello to Resign as Clarient Chief Financial Officer
7. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
8. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
9. Clarient to Commercialize Novel Breast Cancer Profile
10. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
11. Cynvec to Present at the 11th Annual Shanghai International Forum on Biotechnology and Pharmaceutical Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Feb. 20, 2017  Former NFL players who had repeated ... later in life, according to a preliminary study released today ... 69th Annual Meeting in Boston , April ... complex movements where the muscles and nerves work together, like ... ...
(Date:2/19/2017)... ... February 19, 2017 , ... ... Corporation ventured outside of weighing equipment with the goal of expanding the reach ... mind, the line of Starter water analysis meters were introduced into the market ...
(Date:2/18/2017)... ... February 17, 2017 , ... A ... in Hong Kong. , Nerium International is proud to introduce its Age-Defying Night ... Cream, NeriumAD™ Formula to consumers across Hong Kong. The luxury skincare products contain ...
(Date:2/17/2017)... , Feb. 17, 2017  BioGenex, a global ... development of a novel system for quantitative immunohistochemistry ... the University of Rochester (NY, USA) and Konica-Minolta ... new system is able to accurately quantify the ... (Human epidermal growth factor receptor-2) in clinical samples. ...
Breaking Biology Technology:
(Date:2/8/2017)... -- Report Highlights The global biosurgery market ... in 2016 at a compound annual growth rate (CAGR) ... - An overview of the global market for biosurgery. ... 2015 and 2016, and projections of compound annual growth ... on the basis of product type, source, application, and ...
(Date:2/7/2017)... 2017 Ipsidy Inc. ( www.ipsidy.com ... IDGS], ("Ipsidy" or the "Company") a provider of secure, ... is pleased to announce the following changes as part ... January 31, 2017, Philip D. Beck was ... President.  An experienced payment industry professional and public company ...
(Date:2/3/2017)... 3, 2017 A new independent identity strategy ... LLP (IdSP) . Designed to fill a critical niche ... market, founding partners Mark Crego and ... just in identity expertise that span federal governments, the ... The Crego-Kephart combined expertise has a common theme born ...
Breaking Biology News(10 mins):